Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track KTTA with free AI briefings, catalyst countdowns, and dilution alerts.

KTTA · Pasithea Therapeutics Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$45.7M Cash on Hand

28.9mo Cash Runway

Follow KTTA by email Get an email when KTTA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KTTA, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Sep 2027 · Phase 1 · Recruiting · PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
MEK1/2 Inhibitor PAS-004	RAS Mutation	Phase 1 · NCT06299839	Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KTTA holds $45.7M in cash and short-term investments (as of Jun 30, 2026) and burns about $4.7M/quarter from operations, an estimated runway of 28.9 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KTTA files for a raise →

Get the full KTTA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KTTA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z